This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharmaceuticals Inc.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Harpal Gill: Innovator in Dopamine D3 Receptor Ligands
Introduction
Harpal Gill is a notable inventor based in West Chester, OH (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target dopamine D3 receptors. His work has implications for treating various central nervous system disorders.
Latest Patents
Harpal Gill holds a patent for "Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands." This invention relates to heterocyclic substituted amide derivatives that exhibit selective binding to dopamine D3 receptors. The patent outlines a method for treating central nervous system disorders associated with dopamine D3 receptor activity. The disorders that may be treated with these compounds include psychotic disorders, substance dependence, substance abuse, dyskinetic disorders such as Parkinson's Disease, dementia, anxiety disorders, sleep disorders, circadian rhythm disorders, and mood disorders. The invention also covers processes for preparing these compounds and their use as imaging agents for dopamine D3 receptors.
Career Highlights
Harpal Gill is currently associated with Aventis Pharmaceuticals Inc., where he continues to innovate in the field of medicinal chemistry. His work has led to advancements in understanding and treating complex neurological conditions.
Collaborations
Harpal has collaborated with notable colleagues such as Paul Justin Mueller and John G Jurcak, contributing to a dynamic research environment that fosters innovation.
Conclusion
Harpal Gill's contributions to the field of pharmacology, particularly through his patent on dopamine D3 receptor ligands, highlight his role as a key innovator in addressing central nervous system disorders. His work continues to pave the way for new therapeutic approaches.